Summary of the technology
Toll-like receptors, receptors of the innate immunity, play a critical role in the development of many pathological states, in acute and chronic inflammatory processes. Therefore, TLRs represent a new direction for immunotherapy. In order to discover novel ligands interacting with TLRs, Iterative Stochastic Elimination, an innovative beyond-state-of the-art in Silico method for predicting the chances of molecular bioactivity were employed (HUJI IDR). The most promising drug candidates were verified by a cell-based test-system (Fraunhofer IGB) that allows TLR antagonists/agonist to be identified in a reporter gene assay. The ISE process in addition with the assay lead to novel immune modulating therapeutics
Project ID : 6-2015-3128
Description of the technology
Life Sciences and Bio Technology
Iterative Stochastic Elimination (ISE), Ligands, TLRs
Current development stage
TRL3 - hypothesis testing and intial POC demonstrated in limited # of in-vitro models
- Toll-like receptors (TLRs) have been implicated in several autoimmune and inflammatory diseases, including cancer, diabetes, cardiovascular disease, atherosclerosis, Alzheimer’s disease, and chronic neuropathic pain.
- Currently, most of these life-threatening diseases do not have any treatments available in the market, representing unmet medical needs.
- Three-dimensional structural data showing the ligand recognition mechanisms of all human TLRs (except for TLR10) have been deposited in public domains and encourage the development of TLR modulators (agonists and antagonists) to achieve various therapeutic goals.
A novel immune modulating therapeutics based on 18 small molecules antagonists candidates newly discovered
- Modulate immune response
- Block multiple TLRs
- Can be activated by endogenous molecules
- Can be activated by low molecular weight synthetic compounds
- Human TLRs can elicit overlapping yet distinct immune responses because of their ability to recognize an overlapping set of molecular patterns. Therefore, potent poly TLR antagonists need to be developed to block multiple TLRs.
- A cell-based assay that mimics the innate immune system that includes all 10 human TLR-receptors was developed, screening 1.8 million molecules, providing 68 top candidates which were evaluated in an assay based on TLR9.
- The process includes TLR9 data selection and preparation, followed by ISE algorithm method, MCC scoring method, virtual screening and in-vitro tests on cell-line.
- Further candidate improvement was done using applicability domain filtering and solubility filtering.
Fig. 1: Schematic representation of the assay for TLR9 compound screening. Both antagonist and the specific ligand CpG ODN are added to the cell line leading to a blocking of TLR9.
- Multi-targeted drugs development with simpler pharmacokinetics, lower drug resistance and greater dosing flexibility than traditional “one target-one drug”, “cocktails drugs” and “linked drugs”.
- New drugs against viral infections, dermatologic, autoimmune and inflammatory diseases
- Discovery of novel and different molecular active structures.